Jan 07, 2025
Chimerix Submits Dordaviprone NDA for Accelerated Approval to FDA for Recurrent H3 K27M-Mutant Diffuse Glioma Chimerix announced the submission of a NDA to the FDA for dordaviprone. The application seeks accelerated approval for the treatment of recurrent H3 K27M-mutant diffuse glioma, a rare and aggressive brai...
Read More...
Sep 03, 2021
Charcot-Marie-Tooth (CMT) disease is a rare, chronic and sensory neuropathy that causes weakness of the limbs and progresses gradually over time. It can lead to atrophy, sensory loss and complete limb dysfunction. However, rare, the condition is the most common inherited disorder that damages peripheral nerves with...
Read More...
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Newsletter/Whitepaper